Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients across Turkey: Prospective Multicenter Observational 3K Registry Study

Basit Öğe Kaydı
dc.authorscopusid7003283666
dc.authorscopusid6603414247
dc.authorscopusid7004204730
dc.authorscopusid55888626900
dc.authorscopusid7003407765
dc.authorscopusid6507322668
dc.authorscopusid26649457100
dc.contributor.authorAkarca U.S.
dc.contributor.authorUnsal B.
dc.contributor.authorSezgin O.
dc.contributor.authorYalcin K.
dc.contributor.authorAkdogan M.
dc.contributor.authorGonen C.
dc.contributor.authorGunduz F.
dc.date.accessioned2024-08-04T20:01:01Z
dc.date.available2024-08-04T20:01:01Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAims: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey. Methods: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study. Data on patient characteristics, etiologies of HCC, laboratory values, and tumor characteristics and stages were recorded at study enrollment. Results: HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and NAFLD (3.5%), as the major etiologies. Considering that 51.6% of the patients had >5 cm HCC, 44% were Child-Pugh B/C and 57% were BCLC B-D, it appears that a significant group of HCC patients were diagnosed at advanced stages. Of 540 patients, 271 (50.2%) were referred or applied with the diagnosis of HCC. Patients with HCC at presentation had larger tumor size (median (min-max) 6.6 (0-30) vs. 4.8 (0-90) cm, P <.001) and more advanced BCLC stage (Stage C-D in 40.8% vs. 26.4%, respectively, P =.005), compared to patients who were diagnosed during follow-up. Conclusions: Our findings revealed that HBV infection was the leading etiology and a moderate-to-advanced disease was evident in more than half of patients at the time of diagnosis. HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage. © 2021 by The Turkish Society of Gastroenterologyen_US
dc.description.sponsorshipthank Cagla Ayhan, MD and Sule Oktay, MD, PhD, from KAPPA Consultancy Training Research Ltd., Istanbul, who provided editorial support funded by Bayer Turk.en_US
dc.description.sponsorshipFinancial Disclosure: This study was supported by Bayer Turk. Ween_US
dc.identifier.doi10.5152/tjg.2021.201171
dc.identifier.endpage1028en_US
dc.identifier.issn1300-4948
dc.identifier.issue12en_US
dc.identifier.pmid34876392en_US
dc.identifier.scopus2-s2.0-85122498900en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1019en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2021.201171
dc.identifier.urihttps://hdl.handle.net/11616/91207
dc.identifier.volume32en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectepidemiologyen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectprognostic factorsen_US
dc.subjectrisk factorsen_US
dc.subjectscreeningen_US
dc.subjectTurkeyen_US
dc.titleCharacteristics of Newly Diagnosed Hepatocellular Carcinoma Patients across Turkey: Prospective Multicenter Observational 3K Registry Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu